Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the frontline treatments in chronic myeloid leukemia (CML). Growing evidence has shown that TKIs also enhance immunity. Since gamma-delta T (γδT) cells possess the potent anticancer capability, here we investigated the potential involvement o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yu-Cheng, Chiang, Yi-Hao, Hsu, Kate, Chuang, Chih-Kuang, Kao, Chen-Wei, Chang, Yi-Fang, Chang, Ming-Chih, Lim, Ken-Hong, Cheng, Hung-I, Hsu, Yen-Ning, Chen, Caleb G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595379/
https://www.ncbi.nlm.nih.gov/pubmed/34785653
http://dx.doi.org/10.1038/s41408-021-00572-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595379/
https://www.ncbi.nlm.nih.gov/pubmed/34785653
http://dx.doi.org/10.1038/s41408-021-00572-7

Ejemplares similares